Unity Bancorp Inc

Unity Software posted a 17% revenue increase in Q1 2026, fueled by its AI-powered ad engine, but a $279 million impairment charge widened its net loss to $347 million.

Unity Software's stock jumped 11% to $19.01 following an improved first-quarter outlook and a strategic decision to divest slower-growth advertising and publishing units.

ImmunityBio shares tumbled 21.1% following an FDA warning letter alleging false or misleading promotional claims about its cancer therapy Anktiva. The drug generated essentially all of the company's $113 million in 2025 revenue.

ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.

ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.

Unity Software shares dropped nearly 10% following a weak first-quarter revenue forecast and analyst warnings about competitive threats from artificial intelligence.

Unity shares held near $21.41 in premarket trading following a 26% plunge after the company issued weaker-than-expected Q1 revenue guidance. Investors are monitoring demand for its Create tools and advertising segment.

ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.